시장보고서
상품코드
1090052

세계의 레트증후군 시장 규모 : 유형별, 치료법별, 투여 경로별, 최종사용자별, 지역별 예측(2022-2028년)

Global Rett Syndrome Market Size study, By Type, By Treatment, By Route of Administration, and By End User, and Regional Forecasts 2022-2028

발행일: | 리서치사: Bizwit Research & Consulting LLP | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 레트증후군 시장에 대해 조사분석했으며, 시장 동향, 업계 분석, COVID-19의 영향, 부문별·지역별 시장 분석, 기업 개요 등을 정리하여 전해드립니다.

목차

제1장 개요

제2장 세계의 레트증후군 시장 정의와 범위

제3장 세계의 레트증후군 시장 역학

  • 레트증후군 시장의 영향 분석(2020-2028년)

제4장 세계의 레트증후군 시장 업계 분석

  • Porter's 5 Force 모델
  • PEST 분석
  • 투자 채택 모델
  • 애널리스트의 추천 사항과 결론
  • 주요 투자 기회
  • 주요 성공 전략

제5장 리스크 평가 : COVID-19의 영향

    • 업계에 대한 COVID-19의 전체적인 영향 평가
    • COVID-19 이전·COVID-19 이후 시장 시나리오

제6장 세계의 레트증후군 시장 : 유형별

  • 시장 스냅숏
  • 실적·잠재성 분석 : 유형별
  • 추정과 예측 : 유형별(2018-2028년)
  • 하위 부문 분석
    • 전형적 레트증후군
    • 비정형 레트증후군

제7장 세계의 레트증후군 시장 : 치료법별

  • 시장 스냅숏
  • 실적·잠재성 분석 : 치료법별
  • 추정과 예측 : 치료법별(2018-2028년)
  • 하위 부문 분석
    • 투약
    • 물리치료
    • 작업치료
    • 언어 요법
    • 영양 지원

제8장 세계의 레트증후군 시장 : 투여 경로별

  • 시장 스냅숏
  • 실적·잠재성 분석 : 투여 경로별
  • 추정과 예측 : 투여 경로별(2018-2028년)
  • 하위 부문 분석
    • 경구
    • 비경구
    • 기타

제9장 세계의 레트증후군 시장 : 최종사용자별

  • 시장 스냅숏
  • 실적·잠재성 분석 : 최종사용자별
  • 추정과 예측 : 최종사용자별(2018-2028년)
  • 하위 부문 분석
    • 병원
    • 전문 클리닉
    • 기타

제10장 세계의 레트증후군 시장 : 지역 분석

  • 지역 시장 스냅숏
  • 북미
    • 미국
    • 캐나다
  • 유럽 스냅숏
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양 스냅숏
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카 스냅숏
    • 브라질
    • 멕시코
  • 기타 지역

제11장 경쟁 정보

  • 주요 시장 전략
  • 기업 개요
    • Merck KGaA(Germany)
    • Eisai Co., Ltd.(Japan)
    • AstraZeneca(U.K.)
    • Sanofi(France)
    • Novartis AG(Switzerland)
    • Abbott(U.S.)
    • F. Hoffmann-La Roche Ltd.(Switzerland)
    • Teva Pharmaceutical Industries Ltd.(Ireland)
    • Pfizer Inc.(U.S.)
    • GlaxoSmithKline plc(U.K.)

제12장 조사 프로세스

KSA 22.06.28

Global Rett Syndrome Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Rett Syndrome can be defined as a rare genetic neurological and developmental disorder that affects the development of the brain. Rett syndrome are caused by a mutation (a change in the DNA) in the MECP2 gene. Rett syndrome is mostly found in females and begins between 8 and 11 years of age and progresses with age. There are different symptoms of Rett Syndrome such as slowed head growth, abnormal hand movements, hyperventilating, screaming, and crying for no obvious reason, difficulty with movement and coordination, and a loss of social interaction and communication. The rising prevalence of neurological disorders and increasing per capita healthcare spending as well as recent approvals from regulatory authorities are accelerating the global market demand. For instance, according to Pan American Health Organization (PAHO) estimates - In 2019, globally Neurological disorders accounted for 533,172 deaths. Around 213,129 (40%) deaths reported in men, whereas around 320,043 (60%) deaths were reported in women. Furthermore, as per The National Center for Biotechnology Information, USA - as of 2020, worldwide 1 in 20 000-40 000 people affected by Rett Syndrome. RTT is most common genetic causes of developmental and intellectual impairment in girls and affects up to 1 in 10 000 girls under the age of 12. Moreover, in April 2022, US based Taysha Gene Therapies launched clinical development of its gene replacement therapy named TSHA-102 for treatment of Rett Syndrome. The company decided to conduct clinical trial after it recently received approval of a clinical trial application (CTA) by Health Canada. The Sainte-Justine Mother and Child University Hospital Center, in Montreal, would be the initial sites for clinical trials. Also, growing number of R&D activities in healthcare sector. And surging healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost and stringent government regulations impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Rett Syndrome Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to growing healthcare expenditure and presence of leading healthcare players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing awareness towards neurological disorders and increasing penetration of leading healthcare companies in the region, would create lucrative growth prospects for the global Rett Syndrome Market across the Asia Pacific region.

Major market players included in this report are:

Merck KGaA (Germany)

Eisai Co., Ltd. (Japan)

AstraZeneca (U.K.)

Sanofi (France)

Novartis AG (Switzerland)

Abbott (U.S.)

F. Hoffmann-La Roche Ltd. (Switzerland)

Teva Pharmaceutical Industries Ltd. (Ireland)

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type

Classic Rett Syndrome

Atypical Rett Syndrome

By Treatment

Medication

Physical Therapy

Occupational Therapy

Speech language Therapy

Nutritional Support

By Route of Administration

Oral

Parenteral

Others

By End User

Hospitals

Specialty Clinics

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Rett Syndrome Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Global Rett Syndrome Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Global Rett Syndrome Market, by Type, 2020-2028 (USD Million)
    • 1.2.3. Global Rett Syndrome Market, by Treatment, 2020-2028 (USD Million)
    • 1.2.4. Global Rett Syndrome Market, by Route of Administration, 2020-2028 (USD Million)
    • 1.2.5. Global Rett Syndrome Market, by End User, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Rett Syndrome Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Rett Syndrome Market Dynamics

  • 3.1. Rett Syndrome Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of neurological disorders.
      • 3.1.1.2. Increasing per capita healthcare spending.
      • 3.1.1.3. Recent approvals from regulatory authorities.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost
      • 3.1.2.2. Stringent government regulations.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising number of R&D activities in healthcare sector.
      • 3.1.3.2. Growing healthcare infrastructure in emerging economies.

Chapter 4. Global Rett Syndrome Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Rett Syndrome Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Rett Syndrome Market by Type, Performance - Potential Analysis
  • 6.3. Global Rett Syndrome Market Estimates & Forecasts by Type 2018-2028 (USD Million)
  • 6.4. Rett Syndrome Market, Sub Segment Analysis
    • 6.4.1. Classic Rett Syndrome
    • 6.4.2. Atypical Rett Syndrome

Chapter 7. Global Rett Syndrome Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Rett Syndrome Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Rett Syndrome Market Estimates & Forecasts by Treatment 2018-2028 (USD Million)
  • 7.4. Rett Syndrome Market, Sub Segment Analysis
    • 7.4.1. Medication
    • 7.4.2. Physical Therapy
    • 7.4.3. Occupational Therapy
    • 7.4.4. Speech language Therapy
    • 7.4.5. Nutritional Support

Chapter 8. Global Rett Syndrome Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Rett Syndrome Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Rett Syndrome Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
  • 8.4. Rett Syndrome Market, Sub Segment Analysis
    • 8.4.1. Oral
    • 8.4.2. Parenteral
    • 8.4.3. Others

Chapter 9. Global Rett Syndrome Market, by End User

  • 9.1. Market Snapshot
  • 9.2. Global Rett Syndrome Market by End User, Performance - Potential Analysis
  • 9.3. Global Rett Syndrome Market Estimates & Forecasts by End User 2018-2028 (USD Million)
  • 9.4. Rett Syndrome Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

Chapter 10. Global Rett Syndrome Market, Regional Analysis

  • 10.1. Rett Syndrome Market, Regional Market Snapshot
  • 10.2. North America Rett Syndrome Market
    • 10.2.1. U.S. Rett Syndrome Market
      • 10.2.1.1. Type estimates & forecasts, 2018-2028
      • 10.2.1.2. Treatment estimates & forecasts, 2018-2028
      • 10.2.1.3. Route of Administration estimates & forecasts, 2018-2028
      • 10.2.1.4. End User estimates & forecasts, 2018-2028
    • 10.2.2. Canada Rett Syndrome Market
  • 10.3. Europe Rett Syndrome Market Snapshot
    • 10.3.1. U.K. Rett Syndrome Market
    • 10.3.2. Germany Rett Syndrome Market
    • 10.3.3. France Rett Syndrome Market
    • 10.3.4. Spain Rett Syndrome Market
    • 10.3.5. Italy Rett Syndrome Market
    • 10.3.6. Rest of Europe Rett Syndrome Market
  • 10.4. Asia-Pacific Rett Syndrome Market Snapshot
    • 10.4.1. China Rett Syndrome Market
    • 10.4.2. India Rett Syndrome Market
    • 10.4.3. Japan Rett Syndrome Market
    • 10.4.4. Australia Rett Syndrome Market
    • 10.4.5. South Korea Rett Syndrome Market
    • 10.4.6. Rest of Asia Pacific Rett Syndrome Market
  • 10.5. Latin America Rett Syndrome Market Snapshot
    • 10.5.1. Brazil Rett Syndrome Market
    • 10.5.2. Mexico Rett Syndrome Market
  • 10.6. Rest of The World Rett Syndrome Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Merck KGaA (Germany)
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Eisai Co., Ltd. (Japan)
    • 11.2.3. AstraZeneca (U.K.)
    • 11.2.4. Sanofi (France)
    • 11.2.5. Novartis AG (Switzerland)
    • 11.2.6. Abbott (U.S.)
    • 11.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 11.2.8. Teva Pharmaceutical Industries Ltd. (Ireland)
    • 11.2.9. Pfizer Inc. (U.S.)
    • 11.2.10. GlaxoSmithKline plc (U.K.)

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제